false 0001796280 0001796280 2024-06-12 2024-06-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 12, 2024

 

 

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39269   47-1787157

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

   (IRS Employer
Identification No.)

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.0001 per share   ORIC   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 12, 2024, ORIC Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders. Of the 67,422,307 shares of common stock outstanding as of April 17, 2024, the record date for the meeting, 55,977,110 shares of common stock were represented at the meeting in person or by proxy, constituting 83.02% of the outstanding common stock entitled to vote. The matters voted upon at the meeting and the vote with respect to each such matter are set forth below:

Proposal 1 - Election of Directors

Election of two Class I directors to hold office until the 2027 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class I director, to hold office until the Company’s 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.

 

Nominees

    For      Withheld      Broker Non-Votes  

Richard Heyman, Ph.D.

      36,581,862        11,942,627        7,452,621  

Lori Kunkel, M.D.

      48,020,921        509,099        7,447,090  

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

55,632,738   6,150   338,222   0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ORIC PHARMACEUTICALS, INC.
Date: June 14, 2024     By:  

/s/ Christian V. Kuhlen, M.D.

     

Christian V. Kuhlen, M.D.

General Counsel

v3.24.1.1.u2
Document and Entity Information
Jun. 12, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001796280
Document Type 8-K
Document Period End Date Jun. 12, 2024
Entity Registrant Name ORIC Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39269
Entity Tax Identification Number 47-1787157
Entity Address, Address Line One 240 E. Grand Ave
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 388-5600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ORIC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Oric Pharmaceuticals (NASDAQ:ORIC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Oric Pharmaceuticals.
Oric Pharmaceuticals (NASDAQ:ORIC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Oric Pharmaceuticals.